Previous Article | Next Article ![]()
Journal of Clinical Microbiology, November 2002, p. 4332-4333, Vol. 40, No. 11
0095-1137/02/$04.00+0 DOI: 10.1128/JCM.40.11.4332-4333.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
The JONES Group/JMI Laboratories, North Liberty, Iowa 52317
Received 17 May 2002/ Accepted 19 August 2002
The revised interpretive criteria for Streptococcus pneumoniae recently published in the NCCLS M100-S12 informational supplement provide two sets of breakpoints for some cephalosporins: one set for meningeal infection isolates and a new set for nonmeningeal infection isolates. The net effect of these changes was to increase the reported rates of susceptibility of S. pneumoniae to the more active parenteral cephalosporins, such as cefepime, cefotaxime, and ceftriaxone, by 9.1 to 13.0%, bringing their in vitro rates much closer to those of amoxicillin (modified in an earlier NCCLS publication). These revised breakpoints will assist the rational prescribing of antimicrobial agents for the treatment of pneumococcal infections for specific types of infection and establish a greater correlation with clinical outcomes.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»